Last reviewed · How we verify
Progesterone vaginal ring
At a glance
| Generic name | Progesterone vaginal ring |
|---|---|
| Also known as | Progering (Trade Mark) |
| Sponsor | Grünenthal GmbH |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
- Vaginal discharge
- Lower abdominal or pelvic pressure
- Vaginal soreness/discomfort
- Lower abdominal or pelvic pain
- Vaginal itching
- Biochemical pregnancy
- Vaginal odor
- Nausea
- Incontinence or change in urinary frequency
- Abortion spontaneous
- Headache
- Vaginal burning
Key clinical trials
- Comparison of Oral Dydrogesterone and Vaginal Progesterone in Menopausal Hormone Therapy (NA)
- Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency (PHASE3)
- First in Human Safety and Ease of Use Assessment of 400mg Progesterone Callavid in Women With Luteal Phase Insufficiency (PHASE1)
- Exogenous Progesterone as Ovulation Trigger (PHASE4)
- A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix (PHASE3)
- Postplacental Copper Intrauterine Device Versus Postpartum Progesterone-only Pills on Uterine Niche Formation (NA)
- Vaginal Versus Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth (PHASE4)
- FET-LET-2x2: Clinical Pregnancy Rates After Frozen Embryo Transfer in Natural and Modified Natural Cycles (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Progesterone vaginal ring CI brief — competitive landscape report
- Progesterone vaginal ring updates RSS · CI watch RSS
- Grünenthal GmbH portfolio CI